Patrick Ansems

The value comes from keeping the two worlds in real-time conversation: bench intelligence adjusts manufacturing parameters, while manufacturing deviations feed back into R&D to shape the next formulation.

• Another post casts the digital thread as the “heart” that carries scientific intent from the lab to the factory floor without losing its beat.
• It ends by asking how others handle handovers between digitized silos, identifying the handover as an unresolved problem.

'From Lab to Line: Scientific intelligence from the bench informing manufacturing parameters instantly. From Line to Lab: Real-world manufacturing deviations flowing back to R&D to optimize the next formulation.'

One post moves from “digital twin” to “closed loop”; another describes the digital thread as the Heart layer of the Digital Organism.

Read original · Original 2

The Mind covers AI, simulation, knowledge graphs and predictive intelligence.

• The Heart is the digital thread or orchestration layer.
• The Body covers laboratories, manufacturing, automation and physical execution.
• The Soul covers people, governance, compliance, trust and patient impact.
• The framework diagnoses whether an organization is building a one-off project or an operating organism.

The Siemens post states, 'Data is the heart.

• Intelligence is the mind.
• Operations are the body.
• And our people are the soul.'

The framework appears first in a conference announcement, then in a recap that incorporates other speakers’ points on Eroom’s Law, context to action and healthcare data spaces.

Read original · Original 2 · Original 3

The posts cite Eroom’s Law, 25% of manufacturing capacity trapped, and more than $300B at risk; they also describe disconnected IT projects as a poor fit for the continuous race to scale therapies.

• The synthesis at the Arvato Systems forum: 'AI is not a data problem.
• It is a context problem.' Ansems attributes Eroom’s Law and the need to absorb AI-generated insights into decision-making to S.
• M.
• Richards; “context to action” in manufacturing to Thomas Halfmann; and healthcare data spaces, interoperability, governance and collaboration to Maro Bader and Ralf Heyder.
• These are the guests’ views; Ansems’s own framing is the context-problem line and the Digital Organism.

'AI is not a data problem. It is a context problem.' The same recap says AI creates value only when organizations can incorporate AI-generated insights into decision-making, and notes discussion of compliance, validation, AI governance and shared responsibility in SaaS.

Read original · Original 2

A post on the updated Siemens Life Sciences Experience Center in Vienna presents its expanded Living Lab and Digi Lab as a mini pharma company, where customers can see discovery, development, manufacturing and operations connected through a digital thread.

• The challenge is the handover: knowledge moves between scientists, process engineers, manufacturing teams, quality teams, suppliers and regulators; data lives in different systems, and context gets lost.
• The priority is One Team and One Tech: software, automation and consulting working together around a common purpose.

The Living Lab and Digi Lab are 'essentially a mini pharma company' where customers can experience how discovery, development, manufacturing and operations connect through a digital thread.

Read original

At the Arvato Systems forum, Patrick Ansems summarizes S.

• M.
• Richards, Thomas Halfmann, Maro Bader and Ralf Heyder, and thanks Arvato Systems, speakers, panelists and participants.
• In the Siemens post, they credit Christian Glaser, Dr.
• Julita Panek and Guillermo Jimeno, describing the project as a One Team and One Tech story.
• Andrew Whytock appears as co-presenter of the Digital Organism.

The forum recap names S.

• M.
• Richards, Thomas Halfmann, Maro Bader and Ralf Heyder, saying their different directions 'arrived at remarkably similar conclusions.' The Vienna post names Christian Glaser, Dr.
• Julita Panek and Guillermo Jimeno as colleagues who turned an idea into reality.

Read original · Original 2 · Original 3

Start here for the central argument linking digital twins to manufacturing execution.

Patrick Ansems draws a line between a digital twin as a snapshot and a closed loop as a strategy.

• The post explains Eroom's Law and argues that the next frontier is keeping lab and factory in real-time conversation.
• It gives two concrete examples: 'From Lab to Line' — scientific intelligence from the bench informing manufacturing parameters instantly — and 'From Line to Lab' — real-world manufacturing deviations flowing back to R&D to optimize the next formulation.
• It closes with a network question: 'We’ve digitized the silos.
• How are you handling the handovers?'

For brands planning a campaign

A vendor pitching digital twins for pharma manufacturing should look beyond visualization. The stronger collaboration angle is the handover between R&D and manufacturing: closed-loop data flow, deviation feedback and shared decision points.

The post announces the updated Siemens Life Sciences Experience Center in Vienna, including an expanded Living Lab and Digi Lab.

• It says people from software, automation and consulting built a place where customers can see how modern therapies are designed, tested, transferred, manufactured and delivered.
• The clearest image is a 'mini pharma company' where discovery, development, manufacturing and operations connect through a digital thread.
• It names the handoff problem: knowledge moves between scientists, process engineers, manufacturing teams, quality teams, suppliers and regulators, while data sits in different systems and context gets lost.
• It closes with: 'Data is the heart.
• Intelligence is the mind.
• Operations are the body.
• And our people are the soul.'

For brands planning a campaign

For technical content collaboration, a live or virtual experience-center demo may be more persuasive than another explainer. The asset can show the digital thread moving from discovery through manufacturing, with named teams and customer walkthroughs.

Patrick Ansems argues that companies treat digital transformation as disconnected IT projects, even as the race to scale therapies continues.

• The post cites the 'Execution Gap', with 25% of manufacturing capacity trapped and over $300B at risk.
• It sets out four layers of the Digital Organism: the Mind (AI, knowledge graphs and simulation), the Heart (the digital thread from lab to factory floor), the Body (lab bench and factory floor grounded in biology and chemistry), and the Soul (human leadership and purpose).
• It announces appearances with Andrew Whytock at the 11th Life Science Symposium in Berlin and a Siemens Living Lab event in Vienna.
• It closes with 'Are you building a project, or are you building an organism?' and 'Twin it.
• Win it.'

For brands planning a campaign

A campaign can use the Digital Organism as a framework for thought-leadership content and event tie-ins. The practical hook is project versus organism: how a pharma manufacturer moves from one-off digital twin projects to an operating model for scaling therapies.

Patrick Ansems reports from the 11th Life Science Forum hosted by Arvato Systems.

• The post summarizes several speakers: S.
• M.
• Richards on Eroom's Law and the need for organizations to absorb AI-generated insights into decision-making; Thomas Halfmann on 'context to action' in manufacturing; and Maro Bader and Ralf Heyder on healthcare data spaces, interoperability, governance and collaboration.
• Its central synthesis is: 'AI is not a data problem.
• It is a context problem.' Patrick and Andrew Whytock presented the Digital Organism.
• The post closes by thanking Arvato Systems and noting conversations around compliance, validation, AI governance and shared responsibility in SaaS.

For brands planning a campaign

For a software vendor, frame AI around decision context and governance, not data volume. A technical collaboration could explore validated decision loops, stage-gate change and who owns the handover from insight to action in pharma manufacturing.

In practice that means scientific intelligence from the bench instantly informing manufacturing parameters, and real-world manufacturing deviations flowing back to R&D to shape the next formulation.

• In a later post the same idea appears as the digital thread — the "heart" that carries scientific intent from the lab to the factory floor without losing its beat.
• Ansems closes that post with a direct question to the network about how others handle handovers between digitized silos.

Builds the argument through contrast — twin versus loop — then lays out the two directions of data flow and hands the question to the audience.

For brands planning a campaign

A vendor selling twin, thread or orchestration software can engage on data architecture rather than product features. A natural collaboration is a technical explainer or working session on how lab-to-line and line-to-lab data move, building on Ansems’ public framing of handovers as an unsolved problem worth discussing.

Examples: Source 1 · Source 2

The Mind covers AI, simulation, knowledge graphs and predictive intelligence.

• The Heart is the digital thread or orchestration layer.
• The Body covers laboratories, manufacturing, automation and physical execution.
• The Soul covers people, governance, compliance, trust and patient impact.
• They presented the framework with Andrew Whytock at Arvato Systems' 11th Life Science Forum and promoted a follow-up demonstration at the Siemens Living Lab event in Vienna.

A consistent analogy applied across posts, with a defined role for each layer and an argument that can be repeated across audiences.

For brands planning a campaign

The framework is portable and named, making it easy for a vendor to use as the spine of a co-authored piece, keynote or workshop, with its product placed in the layer it serves. Working directly with the Mind/Heart/Body/Soul structure avoids a generic sponsored post.

Examples: Source 1 · Source 2

The posts cite 25% of manufacturing capacity sitting trapped, more than $300B at risk, and Eroom's Law — R&D productivity under pressure despite decades of technology and data investment.

• They frame the problem as context rather than data: the challenge is no longer access to data, but turning signals into decisions and decisions into action.
• AI creates value only when an organization can absorb AI-generated insight into its decision-making.

Ask Ansems for sources for the capacity and dollar figures; the posts do not cite them.

For brands planning a campaign

A vendor selling manufacturing, data or analytics software gets a ready-made problem statement for a webinar or technical content pairing. The distinction between a data problem and a context problem offers a hook for positioning infrastructure and integration work rather than dashboards alone.

Examples: Source 1 · Source 2

The stated pride is less in the technology than in how it was built: software, automation and consulting teams working side by side.

For brands planning a campaign

Ansems favors showing over telling. A collaboration built around a demo, lab visit, pilot walkthrough or hands-on technical session will fit their voice better than a text-only sponsorship.

Examples: Source 1

At the Arvato Systems forum, they drew on S.

• M.
• Richards on Eroom's Law and stage-gated decision-making, Thomas Halfmann on "context to action," and Maro Bader and Ralf Heyder on healthcare data spaces, interoperability and governance.
• Hosts, speakers and project colleagues are credited by name, and the same Digital Organism framing runs through the recap.

For brands planning a campaign

Conference recaps and jointly presented sessions are an established format. A vendor can provide a platform — a conference, lab day or joint panel — that gives Ansems material to synthesize and a reason to name the host brand alongside other speakers.

Examples: Source 1 · Source 2 · Source 3

One post also carries a #Siemens tag. The voice is that of someone inside the organization presenting its work, not an outside vendor mention.

View example

The posts cover attending and speaking at a company-hosted event but don't clarify whether the relationship was paid or ongoing; ask for confirmation.

View example

Lewis works mostly in short news roundups and deal announcements—a pharma industry update digest and the completion of an automation and digital manufacturing acquisition—rather than Ansems's framework-driven arguments about closed-loop data flow, the digital thread and the Digital Organism.

Read original · Original 2

Both attribute delays, rework and wasted effort to misalignment and siloed or absent prioritisation, rather than missing data, and both use visual, collaborative ways to show dependencies and bottlenecks.

Hier's material focuses on strategic roadmapping and portfolio prioritisation, including visual roadmap tooling and a MoSCoW prioritisation grid; one post is a personal end-of-year reflection on running a business. Ansems focuses more on manufacturing data architecture, digital twins and the thread between laboratory and factory.

Read original · Original 2

They also examine how regulatory position, CMC, clinical evidence, medical communication and market access must describe the same source of value. Ansems raises similar questions when they contrast building a project with building an organism and argue that scientific intent must survive into manufacturing.

Bham focuses on therapeutic modalities—psychedelic medicine and radiopharmaceuticals—with reimbursement, clinic capacity, isotope supply and regulatory narrative as recurring concerns. Ansems writes about the data and manufacturing architecture that carries a therapy from molecule to market, not a specific treatment class.

Read original · Original 2

Lewis’s post on the Project Farma and PerkinElmer acquisition of SimoTech describes automation and digital manufacturing as connected across the whole facility lifecycle — design, project execution, CQV, start-up, operational readiness and ongoing operations.

• It frames the value as reducing handoffs and aligning engineering, quality, automation, digital systems and operations around shared objectives.
• That’s the same buyer problem Patrick Ansems addresses with the digital thread, but from the delivery and execution side, giving the vendor a natural inroad to operations and CQV leaders who sign off on manufacturing software.
• Lewis also publishes a pharma news roundup covering deals, FDA leadership changes, pricing, manufacturing and funding, creating frequent opportunities for a vendor to be a named source on a development rather than wait for a single flagship collaboration.

The posts show aggregation and transaction framing more than a reusable framework.

• Unlike the Digital Organism, there is no established concept to anchor a vendor’s product, so the vendor would need to supply the structure for a co-authored technical piece.
• The roundup format is deliberately brand-neutral across many companies, limiting how much a single product can feature in a recurring slot without making it feel like advertising.
• A vendor seeking a signature, architecture-led argument anchored by its product should stay with Ansems; one seeking broad reach across manufacturing operations and a steady calendar of mentions should weigh Lewis.

Examples: Source 1 · Source 2

Hier addresses decisions the vendor’s buyer often makes before any technology purchase: how to align research, regulatory, product and commercial goals; prioritise initiatives by strategic value; and visualise dependencies and bottlenecks before they become costly.

• The posts name a specific method and artefact — a MoSCoW grid for collaborative prioritisation, visual roadmaps on SharpCloud through Roelto — and show a partner tool in use, not just describe it.
• A vendor selling portfolio, roadmap or portfolio-visualisation software, or whose sale stalls until a pharma organisation agrees on priorities, gets a closer match here than with Ansems, whose framing assumes the manufacturing problem is understood and focuses on how to connect it.

The posts focus on strategy and portfolio rather than the digital twin, digital thread and manufacturing execution.

• A manufacturing software vendor would need to translate roadmap and alignment language into a product story, losing the technical specificity that makes Ansems’s posts directly usable in a manufacturing sale.
• The posts also show an established tooling relationship under the names Roelto and SharpCloud, so a competing roadmap or portfolio product would face overlap rather than an open position.
• Choose Hier for reach into R&D strategy and portfolio leads; stay with Ansems when the product needs to sit inside a technical manufacturing architecture.

Examples: Source 1 · Source 2

In 'The Amodaia Brief,' Bham takes the fortnight’s developments — a second positive Phase III in generalised anxiety disorder, the first US radioligand therapy approved through an abbreviated generic pathway — and draws out the commercial question: repeatable efficacy, delivery, manufacturing and economics.

• The 'Narrative Integrity' argument — that regulatory position, CMC, clinical evidence, medical communication and access must all describe the same source of value — offers a positioning argument a vendor could co-author.
• The format also gives the vendor a named publication to appear in on a predictable cycle.
• A vendor selling into medical affairs, market access or commercial strategy would find a more natural entry point here than with Ansems.

Bham treats manufacturing as one input in a commercial argument about whether a product is differentiated or equivalent, not as the subject.

• A digital-twin or digital-thread product would sit beside the argument rather than at its centre, while process engineers, manufacturing and automation teams — the product’s actual daily users — would be reached indirectly at best.
• Choose Bham for commercial positioning and an analyst-style written deliverable; choose Ansems for technical credibility with the people who build and run the manufacturing loop.

Examples: Source 1 · Source 2